Cantargia (Q3 Review): Planning for a Pivotal Study of Nadunolimab - Redeye

Redeye comments on Cantargia's third quarter report 2025. Cantargia is planning for a pivotal study in pancreatic cancer in 2026, pending the finalisation of the IL1RAp diagnostic and funding. We have therefore changed our valuation assumptions. A new bispecific antibody, CAN14, is being developed for immunological diseases. The next catalyst is the survival readout of TRIFOUR in TNBC scheduled for this year.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138316/cantargia-q3-review-planning-for-a-pivotal-study-of-nadunolimab?utm_source=finwire&utm_medium=RSS